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Introduction  
 
Periodontitis is defined as a chronic inflammatory disease of the periodontal tissues. 
Inflammatory host response triggered by the accumulation of the bacterial biofilm causes gradual 
destruction of the alveolar bone, and connective tissue loss [1, 2]. Therefore, a perturbation in the 
microbial ecology is instrumental in causation of periodontal disease, in addition to dysregulation 
of local and systemic inflammatory response which can accentuate the disease [1]. 
Periodontal disease was recorded in Guinness World Records in 2001 as the common 
disease of mankind. Severe periodontitis reached the sixth most prevalent condition affecting 743 
million people aged 15–99 years old worldwide. With an overall prevalence of 11.2%, the global 
cost of lost productivity for severe periodontitis has been estimated to be 54 billion USD/year [3-
8].  
Randomized controlled trials (RCTs) are considered the gold standard because they provided 
the strongest evidence for efficacy of clinical interventions which are a critical role in healthcare 
decision making [9, 10]. The characteristics of RCTs such as randomization, prevents bias during 
the different steps of conducting clinical studies [11]. However, they are not always feasible or 
ethical to conduct. 
Absence of registration and protocol submission, in addition to poor documentation in 
biomedical studies can produce bias threats, inefficient knowledge building, misleading results 
and waste valuable resources [12-14]. Other parts of concern related to RCTs are bias, secondary 
publications, registration, and spinning the results. Bias in its several forms promotes in-efficacy 
in knowledge building and over estimating false results [15]. 
A recent systematic review showed that dental journals characterized by suboptimal reporting 
and quality [16, 17]. In biomedicine 50% of research reports were poor and unusable, therefore 
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high amount of waste mandates research to improve reporting [18, 19]. The validity and reliability 
of trial results are largely dependent on the study design and methodology. In 1996, the authors 
of the Consolidated Standards of Reporting Trials (CONSORT) statement issued specific 
guidelines intended to standardize and improve the quality of reporting of RCTs [20].  
In addition, international Committee of Medical Journal Editors (ICMJE) in 2005 
recommended registration of RCT protocols in a public register [21]. The importance of RCT 
registration is to decrease selective reporting of positive finding. Studies showed that only ½ of 
biomedical journals adhered to ICMJE requirement [22]. This illustrates the lack in the 
transparency of the periodontal clinical research [23].  
Therefore, good quality randomized clinical trials are still needed to develop clinical guidelines 
for periodontal management of patients with systemic condition. 
This research project touches two of the most published RCTs in Periodontology, including 
the association between cardiovascular diseases and chronic periodontitis, and the use of 
adjuncts along with periodontal therapy to improve clinical outcomes of periodontitis. 
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Reporting quality and spin in abstracts of randomized clinical trials of periodontal 
therapy and cardiovascular disease outcomes. 
 
Introduction: 
The abstract of randomized clinical trials (RCT) provides the reader with the first account of the 
trial objectives, methodology and results. Therefore, reporting accuracy, clarity and quality have 
a critical role during the initial assessment of the trial and affects the decision to read the full text 
[24]. Furthermore, in many geographic locations, RCT abstracts are often the only section of an 
RCT freely accessible to clinicians [25].   
In recognition of the importance of RCT abstracts, the Consolidated Standards of Reporting Trials 
(CONSORT) for abstracts guidelines [26] were developed as an extension to the original 
CONSORT  addressing clarity, completeness and transparency and ensuring that key trial 
elements are properly reported. Hence, poor reporting refers to omitting important information in 
abstracts as required by the well-defined CONSORT items [25].  
Furthermore, spin, otherwise known as propaganda, is defined as failure to accurately and 
faithfully report the findings of a scientific study in a manner that would affect the reader’s 
perception of the outcomes [27]. The tool for spin assessment in publication abstracts [27] 
identifies reporting practices that constitute an intentional or unintentional attempt to spin the 
results and/or conclusions leading to misreporting and bias. Despite the development of reporting 
and spin guidelines, abstracts in biomedical literature are often characterized by poor reporting 
quality and biased finding interpretation [28-32].   
The impact of poor reporting and spin on the public and professional perception of research 
findings is discernible. In fact, abstracts with high levels of spin were found to be more frequently 
read compared to abstracts of the same trial after being edited to omit spin, and were also more 
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likely to mislead clinicians to accept a clinical intervention as being beneficial despite a non-
significant primary outcome [24]. Moreover, spin in abstracts percolates into media coverage and 
press releases, which in turn generates greater public attention [33]. Paradoxically, articles that 
received greater media attention showed improved citation metrics in subsequent publications 
[34], creating what resembles of a vicious circle of public and scientific misinformation.  
Ever since the publication of the earliest studies indicating a correlation between cardiovascular 
(CVD) disease and periodontitis [35, 36], the findings have received considerable professional 
and public interest. To test causal relationships, several RCTs explored the effect of periodontal 
therapy on CVD outcomes.  Subsequently, the topic has sparked intense debates between 
researchers, caused wide-scale media coverage and public interest, and prompted involved 
professional organizations to issue official statements [37, 38]. 
 
Although multiple periodontal-CVD RCTs have been published, the adherence to the CONSORT 
guidelines and the incidence of spin have not been studied.  Therefore, the aim of this study was 
to evaluate the reporting quality and the incidence of spin in abstracts of RCTs investigating the 
effect of periodontal therapy on CVD disease outcomes. 
 
Materials and Methods: 
Search methods and study selection: 
Studies were retrieved from PubMed, Scopus based on search strategy shown below. In addition, 
we crosschecked 17 trial registration platforms included in the World Health Organization 
International Clinical Trials Registry Platform (ICTRP, www.who.int/trialsearch/) to confirm trial 
registration status and information (Appendix Table 1). The search was conducted for all registers 
on 01/01/2018. 
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Search keywords and limitations or filters for each database were as follows: 
a. Pubmed: ("Lipids"[Mesh] OR "Acute-Phase Proteins"[Mesh] OR "Blood 
Pressure"[Mesh] OR "Arterial Pressure"[Mesh] OR "Hypertension"[Mesh] OR 
"Hypotension"[Mesh] OR "Cholesterol"[Mesh] OR "Cholesterol, LDL"[Mesh] OR 
"Cholesterol, HDL"[Mesh] OR "Cholesterol Esters"[Mesh] OR "Embolism, 
Cholesterol"[Mesh] OR "Cholesterol, VLDL"[Mesh] OR "Cardiovascular 
System"[Mesh] OR "Cardiovascular Infections"[Mesh] OR "Cardiovascular 
Abnormalities"[Mesh] OR "Cardiovascular Diseases"[Mesh] OR "Cardiovascular 
Physiological Phenomena"[Mesh] OR "Endothelium"[Mesh] OR "Endothelial 
Cells"[Mesh]) AND ("Periodontal Debridement"[Mesh] OR "Periodontal 
Diseases"[Mesh] OR "Periodontal Pocket"[Mesh] OR "Alveolar Bone Loss"[Mesh] OR 
"Dental Scaling"[Mesh] OR "Periodontitis"[Mesh] OR "Dental Prophylaxis"[Mesh] OR 
"Periodontal Attachment Loss"[Mesh]) filter: clinical trial 
b. Scopus: TITLE-ABS-KEY ( ( "Lipids"  OR  " Proteins*"  OR  "Pressure*"  OR  
"Hypertension"  OR  "Hypotension"  OR  "Cholesterol"  OR  "Cardiovascular*"  OR  
"Endothelium"  OR  "Endothelial*" )  AND  ( "Periodontal*"  OR  "Alveolar Bone Loss"  
OR  "Dental*"  OR  "Periodontitis" )  AND  "clinical trial" )  AND  ( LIMIT-TO ( DOCTYPE 
,  "ar" ) ) 
c. 17 trial registration platforms (Appendix a) were searched. Since these platforms were 
limited to one or two keywords, “periodont*” was used as a main keyword, then records 
were scanned for eligible studies. 
The retrieved articles were hand-screened for identification of additional RCT reports (Figure 1), 
and then duplicates were excluded.  
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RCT report inclusion criteria: 
1. Study Design:  
Only publications of periodontal-CVD RCTs. Cohort, non-randomized trials or 
observational trials were excluded. RCT publications in languages other than English were 
excluded.  
2. Participants: 
Targeted populations included adult patients with no systemic diseases other than CVD 
diseases. Studies were included if the participants were diagnosed with chronic 
periodontitis only. Studies with participants diagnosed with aggressive periodontitis, 
gingivitis, or peri-implantitis were excluded. 
3. Intervention:   
The tested intervention included either subgingival scaling and root planing (SRP) or SRP 
with adjunctive therapy. Interventional studies employing adjuncts alone, supragingival 
scaling alone or surgical therapy were excluded. 
4. Outcomes:  
True or surrogate CVD outcomes were included. For descriptive purposes, outcomes were 
segregated into two groups [39]: 
a. CVD true events; such as angina, myocardial infarction, stroke, and CVD end 
points; such as CVD related-death. 
b. Surrogate outcomes; such as blood pressure, lipids, blood tests, C-reactive protein 
(hs-CRP), lipoproteins, and blood cell count.   
 
Additional selection criteria for spin assessment: 
Only studies with a clearly defined primary outcome were included in the spin analysis. To fulfill 
this condition, the primary outcome should be either explicitly stated in the abstract or the full text, 
or, in the case that the primary outcome was not explicitly reported, we considered the outcome 
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stated in the sample size calculations. If no outcome was stated in the sample size calculation, 
we deduced a primary outcome based on the stated objectives of the study. If no primary outcome 
could be identified, the study was excluded. In addition, studies with multiple primary outcomes 
were excluded. 
 
Data extraction and compilation: 
1. Selection of studies was carried out according to the inclusion criteria. Titles and abstracts 
of the search results were initially screened to look for possible eligible studies. Then, full 
texts were retrieved and assessed to further assess eligibility. In cases of multiple 
published reports associated with the same trial registration number, the primary 
publication focusing on the RCT results was selected. 
2. Data extraction: Two authors (MS, KA) independently reviewed the abstracts -and the full 
texts, when needed- of the included RCT reports, and applied the CONSORT for abstracts 
and the SPIN checklist [24]. Disagreements were resolved by a third author (EI). Two 
items of the CONSORT abstracts guidelines were excluded because they only apply to 
unpublished studies or conference abstracts. 
3. Characteristics of each RCT abstract and the respective publishing journal were extracted: 
a. Abstract word count 
b. Number of citations as shown on Scopus [40]. 
c. Trial registration number, trial registration date was determined based on the 
information provided by the trial registry. 
d. Trial funding source, number of authors, geographic location, 
e. Trial’s intervention and outcomes.  
f. Journal’s 5 years-impact factor, impact factor without self-citation, influence factor 
as reported on Thomson-Reuters/Clarivate Analytics 2018 [41]. 
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4. A decision-making guide was used to assist calibration and review process [42]. An 
Overall CONSORT Score for reporting quality (OCS) and Overall Spin Score (OSS) were 
calculated for each RCT report based on the CONSORT and Spin checklist.  
Statistical Analysis 
Cohen’s Kappa test will be used to assess inter-rater agreement. For the descriptive analysis 
non-parametric categorical variables were expressed as proportion percent. For the exploratory 
bivariate association between OCS and related variables, we applied a Spearman correlation 
model. The limited sample size did not allow for a further multivariate regression model to assess 
predictors of reporting quality. Statistical analysis was performed with SPSS software (SPSS Inc). 
 
Results: 
1. General findings:  
Twenty-four RCT reports were deemed eligible and entered the analysis (figure 1). Among them, 
one study was a secondary analysis publication (Bizzaro 2017). The PAVE study had multiple 
publications, and according to our inclusion criteria we included only the results publication 
(Offenbacher 2009).  
For each trial, journal and article metrics are presented in Table 1. An overview of other outcomes 
of the included articles is shown Table 2. 
Generally, all RCTs explored surrogate outcomes and none looked into CVD events (Table 2). 
Only 3 abstracts had explicitly stated primary outcome, while for the rest of the RCTs, we had to 
identify and extract the primary outcome from the full text (Table 2). RCTs with more than one 
outcome in the objectives were excluded from spin analysis as primary outcome identification was 
impossible. 
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Table 2 shows that SRP alone was used in 58.3% of the included RCTs, while SRP and adjuncts 
were used in 41.7%. Most o RCTs reported that they were funded (83.3%). Among them, 58% 
were funded intramurally, 46% by foundations, 29% by federal agencies, and 25% by industry. 
60% of the funded RCTs had multiple funding sources. 
Abstract word count for each trial is presented in Table 1, and was categorized into 3 groups 
according to CONSORT findings [26], which is presented in Table 2. 66.7% of the abstracts had 
<250-word count, 25% had word count from 250-300, and 8.3% had word count >300 [26]. 
 
2. CONSORT checklist findings 
Following the RCT abstract assessment, OCS ranged from 2 to 9 out of 15. Table 3 presents the 
frequency of each CONSORT item fulfillment. Specifically, only 50% of the included RCTs 
reported that they were actually randomized clinical trials in the title.  
Only 3 of the studies (13%) included the design of the study in the abstracts (i.e. parallel group, 
crossover, superiority, etc.).  
2.a. Assessment of methods reporting: 
Three items in the methods section lacked reporting in any of the RCTs, including the item 
“participants”, which lacked information about the location of the study and the detailed description 
of the participants that were included, and the item “randomization”, were all of the studies did not 
report the randomization method that was used, and the item “blinding”, were studies did not 
report the level blinding.  The item “intervention” mostly lacked the necessary description of the 
intervention, therefore, only 54% of the RCTs fulfilled this item. 
Most of the study abstracts (92%) included the objectives of the study. Interestingly, only 3 
abstracts (18.5%) explicitly stated the primary outcome.  
 
2.b. Assessment of results reporting: 
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Although 83% of the abstracts included the numbers of randomized populations, only 17% 
included the numbers of analyzed populations as part of the abstract materials and methods 
rather than the results section violating the CONSORT recommendations. Only 1 RCT indicated 
the harms in the abstracts (4%). 
  
2.c. Assessment of conclusion, registration and funding reporting: 
Only 13% discussed the results and conclusion of the primary outcome. Trial registration was 
reported in only 3 abstracts (13%). When the registration record was looked up in the public 
registry websites using the registration number included in the study, it was found that 4 RCTs 
registered retrospectively after the study was initiated and the first subject was recruited. 
 
3. Spin analysis findings 
 
After applying the exclusion criteria as outlined in the methodology, 14 out of the 26 RCT reports 
were included in the spin analysis.  The prevalence and type of spin for the included articles is 
outlined in Table 4. 
Some form of spin in both of the results and conclusions sections was detected in the majority of 
the RCTs (86%). Given that 79% of the included studies failed indicate the primary or secondary 
outcomes in the abstracts, we considered that these studies employed diverse strategies of spin. 
 
In the results section, all items showed some form of spinning. 64% of the studies focused on 
statistically significant secondary outcomes, and on statistically significant within- and between- 
group comparisons of secondary outcomes.  
 
In the conclusion sections, half of the included RCTs (50%) made hyped statements with 43% 
focusing only on significant results regardless if they corresponded to the primary outcome, 7% 
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focusing on another objective, and 7% making treatment recommendations. 64% acknowledged 
statistically non-significant results for the primary outcome yet emphasized the beneficial effect of 
treatment and emphasized other statistically significant results. 
 
4. Bivariate Correlation Analyses: 
The OCS ranged between 2-9 out of 15, which means some articles only had 2 items fulfilled from 
the whole checklist. The maximum number of items that have been fulfilled in one study is 9 out 
of 15 (figure 2). The OSS ranged between 1-13, which means some papers had only 1 item that 
included some sort of spin, and some articles had 13 items that were spun (figure 3). 
Within the limitations of the study, there was no bivariate correlation between the OCS and the 
other variables (P-value >0.05), with the exception of the positive correlation between OCS and 
funding source reporting (correlation coefficient 0.416, P-value: 0.043). In addition, we observed 
a significant correlation between OCS and registration reporting in the abstract (correlation 
coefficient 0.518, P-value: 0.009). In summary, we observed that abstracts that included trial 
registration and funding information were characterized by high reporting quality. 
OSS showed a marginal negative correlation with OCS (correlation coefficient -0.517, P-value: 
0.059), which means the higher the reporting quality in the abstract, the lower the spin. OSS 
showed negative correlation with funding and registration; however, it wasn’t significant. OSS 
showed marginal negative correlation with the number of authors (correlation coefficient of -0.509, 
P-value of 0.063). 
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Discussion: 
Our study evaluated the reporting quality and incidence of spin in the abstracts of 24 RCT 
publications assessing the impact of periodontal interventions on CVD outcomes. To our 
knowledge, this is the first paper that evaluated both reporting quality and spin in abstracts of 
such publications. The overall reporting quality of the included abstracts was deemed to be 
generally poor. Overall, we found that the RCT objectives and numbers of randomized subjects 
were the only most adequately reported items (92% and 83% respectively). All other CONSORT 
items were adequately reported in almost less than 50% of the abstracts. Notably, we found 
limited RCT abstracts with adequate reporting on the exact trial design (17%), method of 
randomization (0%), blinding (0%), number of subjects analyzed (17%), harms (4%), outcomes 
in both trial arms (13%), as well as the interpretation of the results in the conclusions (13%).  Our 
findings were in agreement with other studies in the medical and dental literature confirming 
inadequate reporting according to CONSORT guidelines [29, 43-45]. Surprisingly, even after 
dental journals adhered to the CONSORT for abstracts guidelines [45], those guidelines were not 
systematically reinforced. Therefore, RCT abstracts were still characterized by inadequate 
reporting quality.  
Consistent with other reports, the CONSORT items most adequately reported in the RCT 
abstracts in our study were items related to objectives and numbers randomized. [44, 45]. Journal 
and article characteristics including impact factor or citation metrics were unreliable in predicting 
reporting quality, as confirmed in other studies [46]. The lack of significance in this correlation 
could be also related to the small number of included publications. 
In regard to the spin analysis, it is noteworthy, that 10 of 24 the originally included RCT 
publications were excluded due the lack of an explicitly defined single primary outcome. The use 
of multiple primary outcomes in RCTs might allow researchers to find significance but in the 
absence of adequate power analysis for multiple outcomes, the risk of bias remains high.  
13 
 
The spin analysis according to the Boutron et al criteria [27] showed that various strategies of 
spin were adapted in the included abstracts (n=14). Specifically, spin phenomena in either the 
result or conclusion section of the abstracts were detected in the majority of the studies. Half of 
the abstracts presented a tendency for hyped conclusions. One third of the RCT abstracts 
presented the trial results in a before-after therapy manner focusing on within group analysis, 
highlighting statistical significance and ignoring the between group comparisons as directed by 
the study objectives. More than half of the RCT abstracts emphasized significance in secondary 
outcomes, a commonly used spin strategy, when the primary outcome results were not significant 
(Boutron et al.) 
Our results agreed with other studies in the medical literature that investigated spin strategies and 
misrepresentation of RCT results with various methodologies [27, 46-49].  
Our study has several strengths. We applied strict inclusion criteria and only included RCT 
publications examining the impact of periodontal intervention on CVD outcomes [50]. We 
standardized the data extraction methodology utilizing well defined decision guide and calibration 
between assessors. Therefore, we have demonstrated a high rate of inter-rater agreement with 
any differences resolved by a third evaluator to ensure greatest accuracy in our analysis. Although 
our study focused on RCT abstracts alone and not the full text of the included publications, these 
considerable reporting shortages and/or misrepresentations were a cause for concern given the 
wide attention abstracts receive within the healthcare and media communities. 
Our study also has some inherent limitations. Although the spin assessment is characterized by 
subjectivity, two independent and calibrated reviewers per abstract conducted the data extraction 
and determined the spin strategies. With this method, we aimed to control the magnitude of 
subjectivity. We employed spin analysis previously used by other groups [24, 27, 31, 49]. 
Therefore, our analysis was focused on abstract sections and might have missed additional spin 
strategies present in the full text.  
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It is important to emphasize that although poor reporting quality might not imply poor study design 
[51], it certainly indicates lack of transparency and prevents replication of the experiment [52]. 
Therefore, reporting quality is necessary for the advancement of science [53]. Low quality 
reporting and introduction of spin might be contributing to continued controversy in this field of 
research [54], flawed professional and public perception of research findings [24, 33] and 
continued ill-advised expenditure of valuable time and resources [13].  The responsibility to 
improve reporting of RCTs and avoidance of misrepresentations falls on multiple parties. Journal 
editors and peer reviewers as gatekeepers could reinforce strict practices to ensure adherence 
to CONSORT or other reporting guidelines, and to require trial registration prior to the 
commencement of the trial as recommended by the ICMJE [55]. An additional effort by academic 
institutions, professional organizations, and scientific communities should be exerted to raise 
awareness among the general scientific audience on proper reporting practices and spin 
strategies. The scientific community should embrace post-publication appraisal and critique with 
a goal to improve reporting quality and minimize the incidence of spin. 
Conclusions: Poor adherence to the CONSORT for abstracts guidelines and high levels of data 
“spin” were found in the abstracts of RCTs examining the effect of periodontal therapy on CVD 
outcomes.  Our findings indicate that journal editors and reviewers should demand strict 
adherence to proper reporting guidelines by researchers and article authors to improve quality 
and reduce spin of results. 
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Tables and graphs: 
Table 1: Characteristics of included articles and publishing journal: 
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Table 2: Other data which were collected  
 CHARACTERISTIC N=24 % 
1 Nature of primary outcome   
 CV event 0 0 
 Surrogate outcome 24 100 
2 Identification of primary outcome   
 Explicitly stated in abstracts 3 13% 
 Explicitly stated in full texts 3 13% 
 From sample size calculation 7 29% 
 Implied from objectives 8* 33% 
4 Intervention   
 SRP alone 14 58.3% 
 SRP + adjunct 10 41.7% 
6 Source of funding   
 Foundation 11 46% 
 Industry 6 25% 
 Federal 7 29% 
 Institution 14 58% 
7 Word count   
 <250 16 66.7% 
 250-300 6 25% 
 >300 2 8.3% 
• Had more than one primary outcome, they weren’t included in the spin analysis 
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Table (3): % of fulfillment of CONSORT items across all RCTs: 
CONSORT FOR ABSTRACT CHECK LIST (NUMBER) 
PERCENTAGE  
TITLE  12 (50%) 
TRIAL DESIGN  3 (13%) 
METHODS  
  PARTICIPANTS 0.0% 
  INTERVENTIONS 13 (54%) 
  OBJECTIVE 22 (92%) 
  OUTCOME 3 (13%) 
  RANDOMIZATION (METHOD) 0 (0%) 
  BLINDING (MASKING) 0 (0%) 
RESULTS  
  NUMBERS RANDOMIZED 20 (83%) 
  NUMBERS ANALYZED 4 (17%) 
  OUTCOME 3 (13%) 
  HARMS 1 (4%) 
CONCLUSIONS 3 (13%) 
TRIAL REGISTRATION 3 (13%) 
FUNDING 8 (33%) 
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Table 4: % of fulfillment of SPIN items across all RCTs: 
 
TYPE OF SPIN (NUMBER) 
PERCENTAGE 
1) SPIN IN THE RESULT   
FOCUS ON STATISTICALLY SIGNIFICANT WITHIN-
GROUP COMPARISON 
3 (21%) 
FOCUS ON STATISTICALLY SIGNIFICANT 
SECONDARY OUTCOMES 
9 (64%) 
FOCUS ON STATISTICALLY SIGNIFICANT 
SUBGROUP ANALYSES 
2 (14%) 
FOCUS ON STATISTICALLY SIGNIFICANT MODIFIED 
POPULATION OF ANALYSES (EG, PER-PROTOCOL 
ANALYSES) 
4 (29%) 
FOCUS ON STATISTICALLY SIGNIFICANT WITHIN- 
AND BETWEEN-GROUP COMPARISONS FOR 
SECONDARY OUTCOMES 
9 (64%) 
OTHER SPIN: NO DEFINITION OF PRIMARY OR 
SECONDARY OUTCOMES 
11 (79%) 
  
2) SPIN IN THE CONCLUSIONS  
FOCUS ONLY ON TREATMENT EFFECTIVENESS:   
1. CLAIMING EQUIVALENCE FOR STATISTICALLY 
NONSIGNIFICANT 
RESULTS 
0 (0%) 
2. CLAIMING EFFICACY WITH NO CONSIDERATION 
OF THE STATISTICALLY NONSIGNIFICANT 
PRIMARY OUTCOME 
9 (64%) 
3. FOCUSING ONLY ON STATISTICALLY 
SIGNIFICANT RESULTS 
6 (43%) 
ACKNOWLEDGE STATISTICALLY NONSIGNIFICANT 
RESULTS FOR THE PRIMARY OUTCOME BUT 
EMPHASIZE THE BENEFICIAL EFFECT OF 
TREATMENT 
9 (64%) 
ACKNOWLEDGE STATISTICALLY NONSIGNIFICANT 
RESULTS FOR THE PRIMARY OUTCOME BUT 
EMPHASIZE OTHER STATISTICALLY SIGNIFICANT 
RESULTS 
9 (64%) 
OTHER SPIN IN CONCLUSIONS SECTION:  
1. CONCLUSION RULING OUT AN ADVERSE EVENT 
ON STATISTICALLY NONSIGNIFICANT RESULTS 
0 (0%) 
2. CONCLUSION FOCUSING ON WITHIN-GROUP 
ASSESSMENT 
(BOTH TREATMENTS ARE EFFECTIVE/TREATMENT 
ADMINISTERED IN BOTH GROUPS IS EFFECTIVE 
(EG, ADD-ON STUDIES) 
2 (14%) 
3. RECOMMENDATION TO USE THE TREATMENT 1 (7%) 
4. FOCUS ON ANOTHER OBJECTIVE 1 (7%) 
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5. COMPARISON WITH PLACEBO GROUP OF 
ANOTHER TRIAL 
0 (0%) 
6. STATISTICALLY NONSIGNIFICANT SUBGROUP 
RESULTS REPORTED AS BENEFICIAL 
0 (0%) 
OTHERS: INADEQUATE EXTRAPOLATION TO 
LARGER POPULATION, INTERVENTION OR 
OUTCOME  
12 (86%) 
HYPE 7 (50%) 
  
3) SPIN IN BOTH RESULTS AND CONCLUSIONS 12 (86%) 
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Figure 1: Diagram of search results 
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Additional records identified through 
searching trial registry websites  
(n = 4,452) 
Records after duplicates removed  
(n = 6,384) 
Records screened  
(n =96) 
Records excluded  
(n = 6,288) 
Full-text articles assessed 
for eligibility  
(n =24) 
Full-text articles excluded: 
Cohort studies, non-
randomized trials, 
observational randomized 
trials, aggressive 
periodontitis, gingivitis, 
adjunct without 
periodontal therapy, 
protocols, children as 
population, surgical 
treatment, only 
supragingival scaling, not 
including cardiovascular 
disease patients, outcome 
not related to 
cardiovascular diseases 
(n = 72) 
Studies included in 
qualitative sanalysis 
(n = 24) 
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Figure 2: Overall Consort score (OCS) for each article
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Figure 3: Overall Spin score (OSS) for each article 
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Appendix 
 
Table 1: List of the trials register that were used to identify eligible studies 
 
 
 
 
 
Australian new zealand clinical trials registry (anzctr) 
Brazilian clinical trials registry (rebec)  
Chinese clinical trial register (chictr)  
Clinical research information service (cris), republic of korea 
Clinicaltrials.gov  
Clinical trials registry – india (ctri)  
Eu clinical trials register (eu-ctr)  
German clinical trials register (drks)  
Iranian registry of clinical trials (irct)  
Isrctn.org  
Japan primary registries network (jprn)  
Sri lanka clinical trials registry (slctr)  
The netherlands national trial register (ntr) 
Cuban public registry of clinical trials (rpcec) 
Thai clinical trials registry (tctr) 
Pan african clinical trial registry (pactr) 
Peruvian clinical trial registry (repec) 
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Unusual Findings In A Group Of Studies Evaluating Agents Adjunctive To Scaling 
And Root Planning: Quality Assessment 
 
Introduction 
Scaling and root planing (SRP) is the first mode of therapy for periodontitis and is centered on the 
mechanical removal of supragingival and subgingival bacterial deposits with the objective of 
reducing periodontal inflammation, reducing periodontal probing depths and improving clinical 
attachment levels around the teeth [56-59]. 
The clinical impact of combining SRP with various adjunctive agents has been tested with the aim 
of improving therapeutic outcomes [60-64]. In 2015 the Council on Scientific Affairs of the 
American Dental Association published a systematic review on the effect of different adjuncts on 
clinical attachment level (CAL) as the primary outcome in randomized clinical trials (RCT) [63].  
Results of this systematic review showed that the quality of evidence is only moderate [63]. The 
meta-analysis showed a modest effect size of adjuncts in combination with SRP. However, a 
single research group published a relatively large number of clinical trials on this subject (n=34, 
approximately 4 trials per year) and showed consistent large effect sizes of the various adjunctive 
agents tested and these results haven’t been reproduced. Recent evidence has suggested that 
phase 2 and 3 RCTs require at least on average 2 years to publish [65-69], revealing the 
demanding requirements for RCT publication particularly in high impact journals. A recent 
systematic review and meta-analysis evaluating the adjunctive effects of statins to SRP showed 
promising large effect sizes but warned that the same research group mentioned above produced 
almost all the trials included. A companion report (ref) compared the results of a meta-analysis of 
the results of this single research group to the most recent ADA meta-analysis to identify possible 
causes for the observed difference in effect sizes. 
27 
 
Adequate and complete reporting of RCT’s is crucial in evaluating outcomes and allowing the 
replication of these trials. Hence, the aim of this study is to identify RCT reports on SRP adjuncts 
published by the same group within the last 8 years, and to assess the reporting quality of the 
selected RCTs and trial registration discrepancies.  
 
Materials and Methods: 
1. RCT search methods and identification  
Research was registered in a public registry website: Open Science Framework, 
https://osf.io/4meyd/. To identify the groups of authors with the most frequently published RCTs 
in the field of adjuncts with periodontal therapy, a search was run in Scopus from 2010-2017. 
Simple keywords were used to include most of the RCTs that are related to this topic, and to 
generate the results of this first step: ("periodont*" AND "adjunct*" AND "clinical trial*"). After 
assessing the names of the authors with the most frequently published RCTs. It was shown that 
these authors belong to one group. The names of the authors were hand searched in Scopus and 
Pubmed to retrieve all the RCTs that were published under their names. Duplicates were then 
excluded. 
 
2. RCT report inclusion criteria: 
 
a. Study Design:  
Only randomized controlled trials (including cluster trials and cross-over studies, non-inferiority 
design and superiority designs) were included. Cohort, non-randomized trials or observational 
trials were excluded. RCT reports in languages other than English were excluded. Studies that 
did not report baseline or did not have a minimum follow-up period of 6 months were excluded. 
b. Population and disease: 
28 
 
No distinction in term of patients and the type of periodontitis. RCTs that included gingivitis, 
sensitivity, and peri-implantitis were excluded. 
c. Intervention:   
Only RCTs related to periodontal therapy with SRP and adjuncts were included. RCTs that looked 
into furcation defects were excluded. Adjuncts such as lasers, photodynamic therapy, platelet 
fibrin were excluded. RCTs that included treatments other than SRP were excluded. 
d. Outcomes:  
All possible periodontal parameters; change in probing depth (PD), clinical attachment level 
(CAL), radiographic bone fill, plaque score, and bleeding on probing. 
 
3. Data extraction and compilation: 
A data extraction sheet based on the Cochrane Handbook for Systematic Reviews of 
Interventions guidelines was developed. Two authors (KA, MS) independently extracted the data 
from the studies that were included. Disagreements were resolved by consensus or in 
consultation with a third reviewer (EI). Cohen's Kappa test will be used to assess inter-rater 
agreement. 
From each study, the following information were extracted: 
(1) Quality characteristics of the study (example, registration, population, type of intervention, type 
of periodontal disease, primary and secondary outcomes, inclusion criteria of the sites, sample 
size and sample size calculation, baseline and 6 months results. and sample size). If trial was 
registered, the registry number was used to extract the following additional information from the 
online registration data: 
A. Data from registry website was cross-matched with the data that was extracted from 
the article. 
B. Determine whether there was pre-study power analysis and identification of primary 
and secondary outcome. 
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(2) Characteristics of the journal (year of starting and ending the trial, year of submission, follow-
up period, impact factor). Subsequently, the following variables were defined:  
 A. X: The interval between trial initiation and termination 
 B. Y: The trial follow-up period per protocol. 
 C. When X>Y, trial reporting was deemed realistic. If X=Y, then trial reporting signifies an 
unrealistic process since it implies that all participants were recruited, enrolled, and randomized 
at the first day of the trial, and all interventions completed and the follow-up examinations done 
within the “X” interval. If Y>X, trial reporting was deemed realistic. 
(3) RCT Outcomes to conduct a meta-analysis (to be published in the second part of this study). 
The consolidated standards on reporting trials (CONSORT) statement guidelines were applied to 
assess reporting quality of each RCT. The Analysis of the “abstract” item according to CONSORT 
was excluded since this study focuses on the full text, and considering that abstracts have their 
own CONSORT reporting guidelines.  
Extracted data were entered into a pre-formatted database spreadsheet using Microsoft Excel 
Software (Version 1707, Microsoft).   
Descriptive analysis per CONSORT item. Specifically, every CONSORT item will be scored as 
fulfilled or not fulfilled (each item will be treated categorically), and therefore, analyzed with non-
parametric statistics. For the inter-rater agreement, 0.7 will be used to conclude that there was 
high agreement between the two reviewers. 
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Results: 
1. General findings:  
Thirty-four were deemed eligible (Figure 1).  
Table 1 shows the general data that was retrieved from each RCT. Table 1. A represents the 
bibliometric information of published trials, and Table 1. B represents the chronological 
comparisons between per protocol and published trial.  
One paper didn’t include the baseline data 
2 RCTs reported outcome data in abstracts and not in in the results section. All of the RCTs 
included part of the demographic data in the materials and methods rather than the results 
section.  
 
2. CONSORT checklist findings: 
Table 2 represents the frequency of each CONSORT item fulfillment. The overall CONSORT 
score for the RCTs ranged from 4-12 out of 36.  
Some items were scored as not fulfilled since there were no information were found in the RCTs, 
including: Important changes to methods after trial commencement, any changes to trial 
outcomes after the trial commenced, why the trial ended or was stopped, and binary outcomes 
analysis. 
 
Introduction and objectives: 
The term “Randomization” was included in the title in 94% of the RCTs. 
The item “Scientific background and explanation of rationale” was only fulfilled in 5.9% of the 
RCTs, because most of the RCTs lacked a comprehensive and explanatory literature about the 
chosen adjunct. Phase 1 human clinical trials to assess the safety of the dosages where not cited 
or conducted.  
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47% of the RCTs had a specific objective or hypothesis, the objective/ hypothesis in the rest of 
the RCTs didn’t include a specific outcome, population, or intervention so this item wasn’t fulfilled. 
 
Study design and intervention: 
Trial design had 0% fulfillment because at least one of the design aspects was missing. The 
CONSORT items “Blinding level”, “the number of study’s arms”, and “the allocation ratio” weren’t 
reported in most of the studies. 
Although the outcomes and methods in some trials were either inconsistent with the registration 
or were inconsistent throughout the study, none of the trials reported any changes, and therefore, 
the CONSORT item “changes to methods after commencement of study” scored 0%. 
The CONSORT item “participants’ eligibility criteria” scored a fulfillment score of 0% because 
none of those criteria were reported but rather the included participants’ criteria were reported in 
the materials and methods, and only the sites’ eligibility criteria were included in the methods 
section. 
All articles reported the location where the study took place, however, the dates of recruitment or 
procedures or the follow up were missing, and therefore the CONSORT item “setting and location” 
wasn’t fulfilled.  
67.6% of the RCTs fulfilled the CONSORT item “interventions”, Studies that failed to report the 
details of the intervention in manner allowing its replication were considered not to fulfill this item. 
Only 50% of the RCTs had pre-defined primary and secondary outcomes, the rest did not specify 
which items were primary or secondary, and none of them had the primary outcome included in 
sample size and power analyses. Although some of the RCTs included the primary outcome for 
the sample size analysis, some of the analysis aspects were missing to finalize the sample size, 
such as standard deviation, effect size, and attrition percentages, therefore the CONSORT item 
“specified primary and secondary outcomes” scored as 0 for all the RCTs. 
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None of the RCTs reported any changes to trial outcomes after the trial commenced or gave 
reasons for the change. This item was going to be removed from the checklist since from the 
initial RCTs analysis, none of the RCTs showed any changes in the trail, however after 
discrepancies in the online registry were found this item was kept in the checklist and scored 0. 
 
Randomization and blinding: 
None of the RCTs reported the type/level of randomization, however, 41.2% of the RCTs reported 
the randomization method. 
Only 11.8 of the RCTs reported the mechanism of allocation concealment, the rest of the RCTs 
did not even include it in the methods section.  
Randomization was only implemented in 8.8%. This means most of the RCTs did not fully- report 
the information about who generated the random allocation sequence, who enrolled participants, 
and who assigned participants to interventions. 
Blinding was only fulfilled in 14.7% of the RCTs. Most of the RCTs did not report the level of 
blinding. In some of the RCTS, although the level of blinding was reported, there was a 
discrepancy between the level of blinding that was reported, and the blinded arms.  
 
Outcomes: 
97.1% reported the analysis test that was used to compare the outcomes between the groups, 
and additional analysis was only reported in 23.5% of the RCTs. 
The item “Participant flow” was fulfilled in 29.4% of the RCTs, because only the randomized 
number of participants were included, rather than the randomized number of sites, specially in 
studies that had the analysis on a site level and not on a participant level. 
Only 17.6% of the studies gave reasons why the patients were lost for follow-up. 
The analyzed RCTs included per-protocol follow-up period, but not the initial and the end dates 
of the follow-up period.  
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8.8% of the studies reported baseline demographic and clinical characteristics for each group, 
the other RCTs did not fulfill this item because none reported the groups’ baseline demographic 
data. 
All RCTs followed “per protocol” analysis, and none followed the intent to treat analysis, therefore, 
none of the RCTs fulfilled this item. 
The item “outcome and estimation” scored 0 because none of the trials reported the effect size of 
the results.  
 
Discussion: 
76.5% of the RCTs reported any harms or adverse effects of the adjuncts in the results section. 
Only 1 trial discussed the limitation of the study, none of other RCTs talked about the study’s 
limitations or any potential bias. 
The item “generalizability” only 5.9% of the RCTs fulfilled it, which means only 5.9% of the studies 
did not generalize its results to the overall population, however, the rest of the RCTs did. 
The item “interpretation” in the discussion part scored 0, because all RCTs didn’t discuss the 
harms and benefits of the adjunct. In addition, most of the discussion did not include the findings 
in other literature rather the studies that were included were the ones published by the same 
group.  
Only 20.6% of the trials reported registration number. 
None of the trials reported a pre-published protocol. 
Only 70.6% reported whether the study was funded or not, and the source of funding. 
 
3. Comparison between the published articles and the pre-registered records: 
The 7 RCTs that were registered, were compared to the information that were registered online. 
None of the trials were pre-registered although pre-registration is recommended by international 
committee of medical journal editors (ICMJE). 
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Although RCTs didn’t mention any change of the trial design in the published manuscripts, 
differences between the published papers and the registration information were found. 
Table 3 shows the comparison between the published articles and the pre-registered records. 
Table 3 A shows the data recovered from the published trials, and Table 3 B shows the data 
recovered from clinicaltrials.gov. 
In one RCT, the follow up period in the published paper did not match the registry. In the same 
registry, the period listed was different in each paragraph. 
The Funding source of all the published RCTs did not match with the funding source that was 
reported in the online registry. 
Two of the RCTs had different inclusion criteria in the published trials compared to the online 
registry. 
Only 2 of the published RCTs had reported the same blinding level as in the online registry, the 
rest had a different blinding level. 
One of the RCTs’ online registry had different trial initiation and termination dates compared to 
the same published RCT. 
Three of the trials had different sample enrolment reported in the online registry compared to the 
published trial. 
One trial included participants that were younger in age compared to the age range that was 
proposed in the online registry. 
Three of the trials reported a follow-up period in the published trial that was different compared to 
the online registry. 
One trial did not report the primary outcome in the published RCT but it was reported in the online 
registry. Two trials had different primary outcome reported in the published RCTs compared to 
the online registry. 
 
4. Trial period and follow-up period. 
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According to our variables’ definition in the materials and methods section, were grouped all the 
included RCTs into three categories in Table 4.  
29% of the RCTs their reported dates of initiation and termination of the trial compared to per 
protocol follow-up period is unreliable or problematic, which means the last day of the follow-up 
period wasn’t achieved or the dates that were reported were not reported correctly. 29% of the 
RCTs’ initiation and termination dates deemed un-realistic. Only 38% of the RCTs’ initiation and 
termination dates deemed realistic. 
Publication period was defined as the time between the RCTs’ termination date and submission 
date 
 
 
Discussion: 
Quality reporting of RCT’s is considered essential to allow for an accurate and through appraisal 
of a clinical trial [70, 71]. The identification of bias and poor methodology is only possible with 
complete and transparent reporting practices, which would in turn allow the decision-maker to 
assess the quality of the trial [71]. The CONSORT statement was developed to standardize the 
reporting of RCT’s and includes items to assess the risk of bias and proper study methodology 
[70]. Our study found that the large number of RCT’s published by Pradeep et al on therapeutic 
pharmaceutical agents adjunctive to SRP suffer from poor reporting quality according to the 
CONSORT guidelines. Significantly, items that are important in assessing risk of bias such as 
randomization, blinding and allocation concealment [72-74] were very poorly reported (8.8%, 11.8 
and 14.7% respectively). 
Public trial registries were introduced and trial pre-registration was either mandated or 
encouraged by journal editors to minimize bias [75]. It is intended to discourage researchers from 
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changing study protocols such as the outcomes being assessed, trial size, or follow up time, all 
of which are believed to introduce bias towards significant results and subsequent publication 
bias [76-78]. Only 7 of the 32 RCT’s examined in this study were pre-registered online, and among 
those registered trials, various protocol discrepancies exist between the manuscript and the online 
trial registration record. The detected changes were not reported as is expected in good scientific 
reporting and required by CONSORT guidelines. 
 
Assessment of the reported length of the RCT relative to the follow up period, almost 60% were 
considered either problematic 
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Tables and graphs: 
 
Table 1: A. Bibliometric information of published trials 
 
Title Journal 
Journal 
impact 
factor* 
Journal ICMJE 
adherence  
Journal pre-
registration 
requirement 
Journal 
CONSORT 
adherence 
IRB 
requirement  
Pradeep AR-16 2016 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-5 2013 
Journal of the International Academy of 
Periodontology Not listed Not reported Not reported N Y 
Pradeep AR-1 2016 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-6 2015 
Journal of the International Academy of 
Periodontology Not listed Not reported Not reported N Y 
Pradeep AR-7 2014 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Martande SS-1 2014 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Priyanka N-1 2015 Contemporary Clinical Dentistry Not listed Yes 5/29/18 Encourages Y Y 
Martande SS-2 2015 American Journal of Dentistry 0.76 Not reported Not reported Y N 
Sharma A-1 2012 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Sharma A-2 2012 AG Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Priyanka N-3 2017 
AG 
The international journal of perio and resto 
dentistry Not listed Not reported Not reported N N 
Pradeep AR-14 2013 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Martande S-1 2017 
Journal of Dental Research, Dental 
Clinics, Dental Prospects Not listed Yes 9/14/16 
Require reg # but no 
pre-registration 
requirement N Y 
Pradeep AR-9 2016 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Pradeep AR-12 2017 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Agarwal E-1 2012 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-15 2015 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-11 2016 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Kumari M-1 2016 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Priyanka N-2 2015 
Journal of the International Academy of 
Periodontology Not listed Not reported Not reported N Y 
Pradeep AR-13 2013 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-10 2013 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Kathariya R-1 2014 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Pradeep AR-2 2013 Australian Dental Journal 1.494 Not reported Not reported Y Y 
Pradeep AR-8 2012 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Agarwal E-2 2012 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Bajaj P-1 2012 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Rao NS-1 2013 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
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Sharma A-3 2017 Journal of applied oral science 1.709 Not reported 
Required starting 
Jan 1, 2016 Y Y 
Rao NS-1 2016 Australian Dental Journal 1.494 Not reported Not reported Y Y 
Kumari M-2 2016 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages Y Y 
Pradeep AR-3 2012 Journal of periodontology 3.392 Yes Ŧ 
Required starting 
Jan 1, 2016 Y Y 
Pradeep AR-4 2011 Archives of Oral biology 2.05 Not reported Not reported N N 
Kanoriya R-2 2017 
Journal of Investigative and Clinical 
Dentistry Not listed Not reported Encourages  Y Y 
*According to Thomson Reuters 2017 
Ŧ No date was listed 
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Table 1: B. Chronological comparisons between per protocol and published trial 
 
Title 
Initiation 
date 
Termination 
dates 
Submission 
date 
Publication 
date 
Interval 
between 
initiation and 
termination 
Interval 
between 
termination and 
publication 
Per 
protocol 
follow-up 
Pradeep AR-16 2016 Sep-14 Jun-15 Dec-15 Jul-16 9.1 13.2 9 
Pradeep AR-5 2013 Jun-11 Nov-11 - Apr-13 5.1 - 6 
Pradeep AR-1 2016 Jun-14 Dec-14 Mar-15 Mar-16 6.1 11.8 6 
Pradeep AR-6 2015 Feb-12 Sep-12 - Jul-14 7.1 - 6 
Pradeep AR-7 2014 Feb-12 Jul-12 Mar-13 82015 5.0 28.5 6 
Martande SS-1 2014 Jul-11 Aug-12 5/2013 Feb-16 13.2 33.5 12 
Priyanka N-1 2015 Oct-11 Apr-12 - Jul-15 6.1 - 6 
Martande SS-2 2015 Jan-12 Jul-12 - Jun-15 6.1 - 6 
Sharma A-1 2012 Jul-10 Dec-10 Feb-11 Jan-12 5.1 10.7 6 
Sharma A-2 2012 AG Aug-10 Feb-11 Apr-11 Jan-12 6.1 9.16 6 
Priyanka N-3 2017 AG Apr-12 Oct-12 - Mar-17 6.1 - 6 
Pradeep AR-14 2013 Aug-11 May-12 6/2012 Jul-13 9.1 12.4 9 
Martande S-1 2017 2/2013 Nov-13 May-15 Mar-17 9.1 22.3 6 
Pradeep AR-9 2016 Jul-14 Mar-15 Aug-15 Aug-17 8.1 24.4 9 
Pradeep AR-12 2017 Nov-13 Aug-14 2/2015 Oct-17 9.1 32.1 9 
Agarwal E-1 2012 Sep-10 Jul-11 Oct-11 Sep-12 10.1 11.2 6 
Pradeep AR-15 2015 Jan-14 Jun-14 Nov-14 Jun-15 5.0 7.06 6 
Pradeep AR-11 2016 Aug-13 Jan-14 Mar-14 Aug-16 5.1 29.5 6 
Kumari M-1 2016 Jan-12 Nov-12 Apr-13 Nov-16 10.2 43.6 9 
Priyanka N-2 2015 Feb-12 Sep-12 - Apr-15 7.1 - 6 
Pradeep AR-13 2013 Jan-11 Sep-11 Dec-11 Jan-13 8.1 13.2 9 
Pradeep AR-10 2013 Jan-11 Sep-11 Jan-12 Feb-13 8.1 13.2 6 
Kathariya R-1 2014 Mar-11 Jun-11 Jul-12 Feb-14 3.1 19.3 3 
Pradeep AR-2 2013 Dec-10 Nov-11 Mar-10 Mar-13 11.2 36.5 9 
Pradeep AR-8 2012 Nov-10 Apr-11 May-11 Oct-12 5.0 17.3 6 
Agarwal E-2 2012 Mar-11 Dec-11 Mar-12 Dec-17 9.2 70.0 9 
Bajaj P-1 2012 Dec-10 Jul-11 Nov-11 Nov-12 7.1 12.2 6 
Rao NS-1 2013 Nov-11 Apr-12 May-12 Aug-13 5.1 15.2 6 
Sharma A-3 2017 Mar-10 Apr-11 May-16 May-17 13.2 12.2 6 
Rao NS-1 2016 Jan-11 Nov-11 May-12 Jun-13 10.1 13.2 9 
Kumari M-2 2016 Mar-12 Feb-13 Apr-17 May-17 11.2 1 9 
Pradeep AR-3 2012 Nov-10 Jul-11 Sep-11 Sep-12 8.1 11.5 6 
Pradeep AR-4 2011 Nov-09 Nov-10 - Mar-11 12.2 - 6 
Kanoriya R-2 2017 May-15 Oct-15 Oct-16 Mar-17 5.1 12.2 6 
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Table 2: item fulfilment per CONSORT guidelines checklist 
Section/Topic Item No Checklist item 
Fulfilment 
score 
Fulfilment 
percentage 
Title     
 1a Identification as a randomised trial in the title 32 94.1 
Introduction     
Background and 
objectives 
2a Scientific background and explanation of rationale 
2 5.9 
 2b Specific objectives or hypotheses 16 47.1 
Methods     
Trial design 3a 
Description of trial design (such as parallel, factorial) including 
allocation ratio 0 0 
 3b 
Important changes to methods after trial commencement (such as 
eligibility criteria), with reasons 0 0 
Participants 4a Eligibility criteria for participants 0 0 
 4b Settings and locations where the data were collected 0 0 
Interventions 5 
The interventions for each group with sufficient details to allow 
replication, including how and when they were actually administered 32 67.6 
Outcomes 6a 
Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed 17 50 
 6b 
Any changes to trial outcomes after the trial commenced, with 
reasons 0 0 
Sample size 7a How sample size was determined 0 0 
 7b 
When applicable, explanation of any interim analyses and stopping 
guidelines 0 0 
Randomisation:     
Sequence 
generation 
8a Method used to generate the random allocation sequence 
14 41.2 
 8b 
Type of randomisation; details of any restriction (such as blocking 
and block size) 0 0 
Allocation 
concealment 
mechanism 
9 
Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned 4 11.8 
Implementation 10 
Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions 3 8.8 
Blinding 11a 
If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing outcomes) 
and how 5 14.7 
 11b If relevant, description of the similarity of interventions 0 0 
Statistical 
methods 
12a 
Statistical methods used to compare groups for primary and 
secondary outcomes 33 97.1 
 12b 
Methods for additional analyses, such as subgroup analyses and 
adjusted analyses 8 23.5 
Results     
Participant flow 
(a diagram is 
strongly 
recommended) 
13a 
For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the 
primary outcome 
10 29.4 
 13b 
For each group, losses and exclusions after randomisation, together 
with reasons 6 17.6 
Recruitment 14a Dates defining the periods of recruitment and follow-up 0 0 
 14b Why the trial ended or was stopped 0 0 
Baseline data 15 
A table showing baseline demographic and clinical characteristics 
for each group 3 8.8 
Numbers 
analysed 
16 
For each group, number of participants (denominator) included in 
each analysis and whether the analysis was by original assigned 
groups 0 0 
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Outcomes and 
estimation 
17a 
For each primary and secondary outcome, results for each group, 
and the estimated effect size and its precision (such as 95% 
confidence interval) 0 0 
 17b 
For binary outcomes, presentation of both absolute and relative 
effect sizes is recommended 0 0 
Ancillary 
analyses 
18 
Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified from 
exploratory 0 0 
Harms 19 
All important harms or unintended effects in each group (for specific 
guidance see CONSORT for harms) 26 76.5 
Discussion     
Limitations 20 
Trial limitations, addressing sources of potential bias, imprecision, 
and, if relevant, multiplicity of analyses 1 2.9 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 2 5.9 
Interpretation 22 
Interpretation consistent with results, balancing benefits and harms, 
and considering other relevant evidence 0 0 
Other 
information 
  
  
Registration 23 Registration number and name of trial registry 7 20.6 
Protocol 24 Where the full trial protocol can be accessed, if available 0 0 
Funding 25 
Sources of funding and other support (such as supply of drugs), role 
of funders 24 70.6 
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Table 3: Comparison between the information retrieved from the website registry and the 
published trial 
Table 3 A: Information retrieved from the published trials 
Title Registration  
Trial 
initiation 
Trial 
termination 
Enrollment 
sample Age 
Inclusion criteria (mm) Blinding 
Follow
-up 
Primary 
outcome Sponsor 
PD CAL Bone     
Pradeep AR-
16 2016 2600520 Sep-14 Jun-15 90 25 - 45  ≥5 ≥3 ≥3 
Triple 
masked 9 N/A 
Pharmaceuticals, 
Institutional 
Pradeep AR-
1 2016 
2386020 Jun-14 Dec-14 60 25 - 45  ≥5 ≥3 0 Triple 
masked 
6 CAL Pharmaceuticals, 
Institutional 
Martande S-
1 2017 
2060032 Feb-13 Nov-13 96 30 - 50  ≥5 ≥4 ≥3 Double
? 
6 Radiographic 
defect fill 
Pharmaceuticals, 
Institutional* 
Pradeep AR-
9 2016  
2455869 Jul-14 Mar-15 99 30–50  ≥5 ≥4 - 6 ≥3 Double 9 Radiographic 
defect fill 
Pharmaceuticals, 
Institutional 
Pradeep AR-
12 2017 
2274090 Nov-13 Aug-14 70 30 - 50  ≥5 ≥4 ≥3 Double 9 PD N/A 
Pradeep AR-
15 2015 
2283515 Jan-14 Jun-14 70 25 - 55 5_6 4_6 ≥3 Double
? 
6 Complete 
bone defect 
fill 
Pharmaceuticals, 
Institutional 
Pradeep AR-
11 2016 
2048761 Aug-13 Jan-14 65 25–50  ≥5 ≥4 ≥3 Double
? 
6 Radiographic 
defect fill 
Pharmaceuticals, 
Institutional 
* Reported that study wasn’t funded 
 
 
Table 3 B: information retrieved from clinicltrials.gov 
Clinicaltrials.gov 
Title First posted  
Trial 
initiation 
Trial 
termination 
Enrollment 
sample 
Age 
(yrs) Inclusion criteria Blinding 
Follow
-up 
Primary 
outcome Sponsor 
Pradeep AR-
16 2016 11/9/2015 Nov-14 May-15 45 30 -50  
PD ≥5, CAL ≥4, 
bone loss ≥3  Quadruple 6 
Radiographic 
defect depth 
reduction Institutional 
Pradeep AR-
1 2016 
3/11/2015 Jun-14 Dec-14 60 25 - 45  PD ≥5, CAL ≥3 Double 6 CAL 
Institutional 
Martande S-
1 2017 
2/11/2014 Feb-13 Nov-13 96 30 -50  PD ≥ 5 CAL≥ 4, 
bone loss ≥3  
Quadruple 9 Change in 
Radiographic 
intra-bony 
defect depth Institutional 
Pradeep AR-
9 2016  
5/28/2015 Jul-14 Mar-15 104 30 - 50  Pds ≥5, cals ≥4 – 6, 
bone loss ≥3  
Double 9 PD 
Institutional 
Pradeep AR-
12 2017 
10/24/2014 Nov-13 Aug-14 70 30 - 50  PD ≥ 5, CAL≥ 4, 
bone loss ≥ 3  
Double 9 PD 
Institutional 
Pradeep AR-
15 2015 
11/5/2014 Jan-14 Jun-14 65 22 - 55  PD of 5- 6, CAL of 4 
- 6 or PD ≥ 7, CAL of 
6 - 9 and bone loss ≥ 
3  
Quadruple 24 
weeks 
Complete bone 
defect fill 
Institutional 
Pradeep AR-
11 2016 
1/29/2014 Aug-13 Feb-14 65 25 - 50  PD ≥ 5, CAL≥ 4, 
bone loss ≥ 3 
Quadruple 6 PD 
Institutional 
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Table 4: Discrepancies in the follow-up period of the RCTs. 
Article Variables (X, Y) Decision 
Pradeep AR-16 2016 X=Y Non-realistic  
Pradeep AR-5 2013 X<Y Problematic/un-reliable 
Pradeep AR-1 2016 X=Y Non-realistic 
Pradeep AR-6 2015 X>Y Realistic  
Pradeep AR-7 2014 X<Y Problematic/un-reliable 
Martande SS-1 2014 X>Y Realistic  
Priyanka N-1 2015 X=Y Non-realistic 
Martande SS-2 2015 X=Y Non-realistic 
Sharma A-1 2012 X<Y Problematic/un-reliable 
Sharma A-2 2012 AG X=Y Non-realistic 
Priyanka N-3 2017 AG X=Y Non-realistic 
Pradeep AR-14 2013 X=Y Non-realistic 
Martande S-1 2017 X>Y Realistic  
Pradeep AR-9 2016 X<Y Problematic/un-reliable 
Pradeep AR-12 2017 X=Y Non-realistic 
Agarwal E-1 2012 X>Y Realistic  
Pradeep AR-15 2015 X<Y Problematic/un-reliable 
Pradeep AR-11 2016 X<Y Problematic/un-reliable 
Kumari M-1 2016 X>Y Realistic  
Priyanka N-2 2015 X>Y Realistic  
Pradeep AR-13 2013 X<Y Problematic/un-reliable 
Pradeep AR-10 2013 X>Y Realistic  
Kathariya R-1 2014 X=Y Non-realistic 
Pradeep AR-2 2013 X>Y Realistic  
Pradeep AR-8 2012 X<Y Problematic/un-reliable 
Agarwal E-2 2012 X=Y Non-realistic 
Bajaj P-1 2012 X>Y Realistic  
Rao NS-1 2013 X<Y Problematic/un-reliable 
Sharma A-3 2017 X>Y Realistic  
Rao NS-1 2016 X>Y Realistic  
Kumari M-2 2016 X>Y Realistic  
Pradeep AR-3 2012 X>Y Realistic  
Pradeep AR-4 2011 X>Y Realistic  
Kanoriya R-2 2017 X<Y Problematic/un-reliable 
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Figure 1: Flowchart of the search strategy  
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